DE69839946D1 - Methoden zum Screening von Affinitätsmarker-Bibliotheken - Google Patents

Methoden zum Screening von Affinitätsmarker-Bibliotheken

Info

Publication number
DE69839946D1
DE69839946D1 DE69839946T DE69839946T DE69839946D1 DE 69839946 D1 DE69839946 D1 DE 69839946D1 DE 69839946 T DE69839946 T DE 69839946T DE 69839946 T DE69839946 T DE 69839946T DE 69839946 D1 DE69839946 D1 DE 69839946D1
Authority
DE
Germany
Prior art keywords
methods
affinity marker
molecule
screening affinity
marker libraries
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69839946T
Other languages
English (en)
Inventor
Alexander Krantz
Wolin Huang
Arthur M Hanel
Darren L Holmes
Dominique P Bridon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ConjuChem Biotechnologies Inc
Original Assignee
ConjuChem Biotechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ConjuChem Biotechnologies Inc filed Critical ConjuChem Biotechnologies Inc
Application granted granted Critical
Publication of DE69839946D1 publication Critical patent/DE69839946D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/0019Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0041Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
    • A61K49/0043Fluorescein, used in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/001Preparation for luminescence or biological staining
    • A61K49/0013Luminescence
    • A61K49/0017Fluorescence in vivo
    • A61K49/005Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056Peptides, proteins, polyamino acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
DE69839946T 1997-11-07 1998-11-06 Methoden zum Screening von Affinitätsmarker-Bibliotheken Expired - Fee Related DE69839946D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6470597P 1997-11-07 1997-11-07
US7792798P 1998-03-13 1998-03-13

Publications (1)

Publication Number Publication Date
DE69839946D1 true DE69839946D1 (de) 2008-10-09

Family

ID=26744806

Family Applications (2)

Application Number Title Priority Date Filing Date
DE69839946T Expired - Fee Related DE69839946D1 (de) 1997-11-07 1998-11-06 Methoden zum Screening von Affinitätsmarker-Bibliotheken
DE69806066T Expired - Lifetime DE69806066T2 (de) 1997-11-07 1998-11-06 Affinitätsmarkierer für menschliches serum albumin

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE69806066T Expired - Lifetime DE69806066T2 (de) 1997-11-07 1998-11-06 Affinitätsmarkierer für menschliches serum albumin

Country Status (8)

Country Link
US (1) US7166695B2 (de)
EP (2) EP1056474B1 (de)
AT (2) ATE406577T1 (de)
AU (1) AU1519699A (de)
CA (2) CA2628053A1 (de)
DE (2) DE69839946D1 (de)
ES (1) ES2178854T3 (de)
WO (1) WO1999024075A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
CA2623458A1 (en) * 1999-05-17 2000-11-23 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
CN101289500A (zh) * 1999-05-17 2008-10-22 康久化学生物技术公司 病毒感染的长效融合肽抑制剂
DE60006100T2 (de) 1999-05-17 2004-07-01 Conjuchem, Inc., Montreal Lang wirkende insulinotrope peptide
US7144854B1 (en) 1999-09-10 2006-12-05 Conjuchem, Inc. Long lasting anti-angiogenic peptides
US6849714B1 (en) 1999-05-17 2005-02-01 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
BR0010757A (pt) 1999-05-17 2002-02-19 Conjuchem Inc Inibidores de peptìdeo de fusão de longa duração de infecção viral
US6706892B1 (en) 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US7090851B1 (en) 1999-09-10 2006-08-15 Conjuchem Inc. Long lasting fusion peptide inhibitors of viral infection
BR0206919A (pt) 2001-02-02 2004-07-06 Conjuchem Inc Derivados de fator de liberação de hormÈnio de crescimento de longa duração
EP1980572A1 (de) 2001-02-16 2008-10-15 ConjuChem Biotechnologies Inc. Glucagonartiges Peptid 2 (GLP-2) mit Langzeitwirkung für die Behandlung von Magendarmerkrankungen und -störungen
WO2002096935A2 (en) 2001-05-31 2002-12-05 Conjuchem, Inc. Long lasting fusion peptide inhibitors for hiv infection
CA2526907C (en) 2003-01-17 2012-11-13 Advanced Proteome Therapeutics, Inc. Tandem analyses of noncovalently driven effectors for modulatory mapping of activities of protein sites
RS20060578A (en) 2004-04-23 2008-11-28 Conjuchem Biotechnologies Inc., Method for the purification of albumin conjugates
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
CN102026666B (zh) * 2007-12-11 2013-10-16 常山凯捷健生物药物研发(河北)有限公司 促胰岛素肽缀合物制剂
JP2019518017A (ja) * 2016-02-09 2019-06-27 アレクサンダー・クランツ トレースレス親和性標識を使用したタンパク質の部位選択的官能化
CA3061467A1 (en) * 2017-04-28 2019-10-24 Ajinomoto Co., Inc. Compound having affinity substance to soluble protein, cleavable portionand reactive group, or salt thereof

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862928A (en) 1969-07-09 1975-01-28 Akzona Inc Psychopharmacological hexa-peptides containing a d-phenylalanyl residue
US4244946A (en) 1979-06-11 1981-01-13 The Salk Institute For Biological Studies Water-soluble peptides affecting gonadal function
US4933288A (en) 1986-11-21 1990-06-12 Cetus Corporation Use of a modified soluble Pseudomonas exotoxin A in immunoconjugates
US4808705A (en) 1986-12-19 1989-02-28 Cetus Corporation Stable formulations of ricin toxin a chain and of RTA-immunoconjugates and stabilizer screening methods therefor
GB8713240D0 (en) 1987-06-05 1987-07-08 Proteus Biotech Ltd Hormones
US4981979A (en) 1987-09-10 1991-01-01 Neorx Corporation Immunoconjugates joined by thioether bonds having reduced toxicity and improved selectivity
DE3731297C1 (de) 1987-09-17 1989-05-18 Rexroth Mannesmann Gmbh Schaltventilanordnung
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
AU633020B2 (en) 1988-07-23 1993-01-21 Novozymes Delta Limited New secretory leader sequences
JPH04501266A (ja) 1988-10-12 1992-03-05 セントコアー,インコーポレーテッド ヨード―125で標識された放射線療法用接合体
US5250662A (en) 1989-10-05 1993-10-05 Alpha Therapeutic Corporation Albumin purification
US5116944A (en) 1989-12-29 1992-05-26 Neorx Corporation Conjugates having improved characteristics for in vivo administration
US5182366A (en) 1990-05-15 1993-01-26 Huebner Verena D Controlled synthesis of peptide mixtures using mixed resins
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5612034A (en) 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
US5843440A (en) 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
ATE176239T1 (de) 1990-11-21 1999-02-15 Iterex Pharma Lp Synthese äquimolarer mischungen vielzähliger oligomere, speziell oligopeptidmischungen
US5616311A (en) 1991-01-15 1997-04-01 Hemosphere, Inc. Non-crosslinked protein particles for therapeutic and diagnostic use
DE69217497T2 (de) 1991-09-18 1997-06-12 Affymax Tech Nv Verfahren zur synthese der verschiedenen sammlungen von oligomeren
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
JPH0692968A (ja) * 1992-09-16 1994-04-05 Nakarai Tesuku Kk ビオチン導入試薬
NZ256952A (en) 1992-09-24 1997-07-27 Chiron Corp Synthesis of n-substituted polyamides and pharmaceutical compositions
US5565324A (en) 1992-10-01 1996-10-15 The Trustees Of Columbia University In The City Of New York Complex combinatorial chemical libraries encoded with tags
US5741893A (en) 1993-08-16 1998-04-21 Hsia; Jen-Chang Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US5571681A (en) 1994-03-10 1996-11-05 The Scripps Research Institute Chemical event selection by suicide substrate conjugates
EP0868427B1 (de) 1995-12-18 2003-05-14 Praecis Pharmaceuticals Incorporated Verfahren zum nachweis von verbindungen die bestimmte zielmoleküle binden
AU713616B2 (en) * 1996-01-12 1999-12-09 Conjuchem, Inc. Cellular and serum protein anchors for diagnostic imaging
US6277583B1 (en) * 1996-02-07 2001-08-21 Conjuchem, Inc. Affinity labeling libraries and applications thereof
US5840733A (en) 1996-07-01 1998-11-24 Redcell, Canada, Inc. Methods and compositions for producing novel conjugates of thrombin inhibitors and endogenous carriers resulting in anti-thrombins with extended lifetimes
WO1998011437A1 (en) 1996-09-16 1998-03-19 Conjuchem, Inc. Affinity labeling libraries with tagged leaving groups
US6203820B1 (en) 1998-05-28 2001-03-20 Brice E. Vickery Compositions and methods for enhancing protein anabolism and detoxification

Also Published As

Publication number Publication date
EP2033661A1 (de) 2009-03-11
US7166695B2 (en) 2007-01-23
WO1999024075A2 (en) 1999-05-20
WO1999024075A3 (en) 1999-09-02
ES2178854T3 (es) 2003-01-01
EP1056474B1 (de) 2002-06-12
DE69806066D1 (de) 2002-07-18
ATE406577T1 (de) 2008-09-15
ATE218892T1 (de) 2002-06-15
CA2305597C (en) 2008-07-29
CA2628053A1 (en) 1999-05-20
US20050037974A1 (en) 2005-02-17
CA2305597A1 (en) 1999-05-20
DE69806066T2 (de) 2003-02-06
AU1519699A (en) 1999-05-31
EP1056474A2 (de) 2000-12-06

Similar Documents

Publication Publication Date Title
ATE406577T1 (de) Methoden zum screening von affinitätsmarker- bibliotheken
DE69602638T2 (de) Naphthylverbindungen, Zwischenprodukte, Zusammensetzungen und Methoden
DE69834596D1 (de) Etectrochirurghische, blutstillende klammervorrichtung
DE69421206D1 (de) Verfahren zum installieren von Klammern
DE69022115D1 (de) Hämostatische, chirurgische Clips.
BR9611436A (pt) D-tartarato de (-)-cis-6(s)-fenil-5(r)-[4-(2-pirrolidin-1-iletóxi) fenil]-5,6,7,8,-tetra-hidronaftalen-2-ol
DE69417960T2 (de) Ungleichgewichtiger Fehlerschutz für kombinierte Informationssignale
DE69731794D1 (de) Innenschutz für eine vaskuläre Anastomose
DE69617007T2 (de) Zweifach härtbares bindemittelsystem
TR200002921T2 (tr) Yarı-Sentetik ekteinasidinler
DE69604261T2 (de) Härtbare, photochromische zusammensetzung
DK1571208T3 (da) Fremgangsmåde til ny faktor IX-rensning
DK1053355T3 (da) PNA- og DNA-konjugater og metoder til fremstilling heraf
DE69806367D1 (de) Rot färbende hyperchromische 3h-naphto(2,1-b)pyranen
DE69818135D1 (de) Verfahren zum Zugriff auf Datenbankinformation
WO2000018439A3 (de) Verwendung von neoangiogenese-markern für diagnose und therapie von tumoren
MA24174A1 (fr) Proteine globuline 11s, utilisable comme marqueur d'imbibition d'une semence au cours de la germination
DE69817104D1 (de) Maschine zum Verpflanzen von Sämlingen
DE69811000T2 (de) System zum Herstellen von Bändern
ATE224387T1 (de) N-(pyridinylamino)isoindoline und verwandte verbindungen
DK1123396T3 (da) Minimale promotorer og anvendelser deraf
DE69312417D1 (de) Chirurgisches Instrument zum Anlegen von Klammern
FR2708942B1 (fr) Fer à repasser à vapeur.
DE69623648D1 (de) Ablenkungsmechanismus fur schiffskörper
NO965050L (no) A- og B-polymorfene av 1-(difenylmetyl)-4- 3-(2-fenyl-1,3-dioksolan-2-yl)propyl -piperazin

Legal Events

Date Code Title Description
8339 Ceased/non-payment of the annual fee